Clearly, further studies are required to explore the potential role for Fas-ASO or inhibitors of Fas signaling in the treatment of NAFLD and (hepatic) insulin resistance as well as the safety of such an approach. The gene discussed is FAS; the disease is metabolic dysfunction-associated steatotic liver disease.